Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 4,875 shares of the company's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $18.60, for a total transaction of $90,675.00. Following the completion of the sale, the chief operating officer now directly owns 2,597 shares in the company, valued at $48,304.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Anish Patel also recently made the following trade(s):
- On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.64, for a total transaction of $76,245.00.
- On Tuesday, February 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.11, for a total transaction of $73,661.25.
- On Monday, January 22nd, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.13, for a total transaction of $73,758.75.
Enliven Therapeutics Trading Up 3.3 %
NASDAQ:ELVN opened at $19.82 on Thursday. The stock has a market capitalization of $816.58 million, a price-to-earnings ratio of -9.05 and a beta of 1.06. The firm has a fifty day simple moving average of $16.43 and a two-hundred day simple moving average of $14.05. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $23.83.
Trump’s last act as President
From Porter & Company | Ad
You’ve probably never heard of Executive Order #13972.
Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines.
For the full story, click here.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.09. Equities analysts predict that Enliven Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a report on Tuesday. They issued a "buy" rating and a $34.00 price target for the company.
View Our Latest Analysis on Enliven Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. AJOVista LLC acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $28,000. Tower Research Capital LLC TRC acquired a new position in shares of Enliven Therapeutics during the first quarter valued at about $36,000. Ameritas Investment Partners Inc. acquired a new position in shares of Enliven Therapeutics during the second quarter valued at about $39,000. Royal Bank of Canada grew its holdings in shares of Enliven Therapeutics by 532.7% during the second quarter. Royal Bank of Canada now owns 3,075 shares of the company's stock valued at $63,000 after buying an additional 2,589 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $66,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
